Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma - LARVOL DELTA

Management of Pediatric Chronic Hepatitis C with Crushed or Split Glecaprevir/Pibrentasvir: A Case Series From East Jeddah Hospital, Saudi Arabia. (PubMed, Int Med Case Rep J) - "This is the first case series of successful pediatric HCV treatment using crushed or Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals split GLE/PIB. This approach may expand treatment options in resource-limited settings where pediatric formulations are unavailable."

Journal • Hepatitis C • Hepatocellular Cancer • Infectious Disease • Inflammation • Oncology • Pediatrics • Solid Tumor

Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024. (PubMed, J Viral Hepat) - "Glecaprevir/pibrentasvir (pan-genotypic regimen) has maintained an average market share of 34% since its introduction in August 2018. Sofosbuvir/velpatasvir/voxilaprevir, listed on the PBS in April 2019, and used for salvage therapy, has had a smaller average market share of 4% since listing...Increasing retreatment rates underscore the need for ongoing monitoring and real-world evaluations. Future head-to-head comparisons may support optimal regimen selection."

Journal • Retrospective data • Fatigue • Hepatitis C • Infectious Disease • Inflammation

Hepatitis C Virus (HCV) treatment during pregnancy using glecaprevir/pibrentasvir (IDWeek 2025) - No abstract available

Hepatitis C • Infectious Disease

Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C. (PubMed, Clin Infect Dis) - P2 | "In this population with elevated risk of onward HCV transmission, 84% were cured with 4 weeks of G/P. Failing this short-course treatment did not compromise retreatment. This study suggests that people with early HCV infection can achieve moderately high cure rates with abbreviated courses of direct-acting antivirals (DAA). Simplified approaches to treatment are critical for HCV elimination and are particularly relevant for populations difficult to retain in care."

Journal • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

HCV Cure Rates in the THINKER-NEXT Trial of Transplanting Kidneys from HCV-Infected Donors into HCV-Negative Recipients (WTC 2025) - P2 | "Patients who failed S/V received Sofosbuvir/Velpatasvir/Voxilaprevir (S/V/V).* From 9/27/2021-1/5/2025, 201 HCV-negative patients were transplanted with a kidney from an HCV-RNA+ donor...196 received 12 weeks of S/V per protocol, while four patients underwent a modified protocol: a) S/V for 26 days due to the development of a perforated duodenal ulcer with prolonged NPO status (n=1); b) 8 weeks of Glecaprevir/Pibrentasvir (G/P) on post-KT day 3 due to initiation of amiodarone immediately post-transplant (n=1); and c) switch from S/V to G/P after initiating amiodarone within the first three weeks of KT (n=2)... In this multi-center trial of transplanting kidneys from HCV-RNA+ donors into HCV-negative recipients, we have demonstrated that with early initiation of HCV treatment within three days of KT, the cure rate with initial treatment is nearly 100%, and to date, all patients have been cured with first or second-line therapy. These data confirm that HCV cure rates..."

Late-breaking abstract • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Peptic Ulcer • Transplantation

Nummular Eczema as the Initial Extrahepatic Manifestation of Hepatitis C Virus Infection: A Case Report. (PubMed, Cureus) - "He was treated with a 12-week course of glecaprevir/pibrentasvir, which resulted in complete resolution of skin lesions and normalization of liver enzymes within one month. No adverse events were recorded. This case highlights the importance of recognizing atypical dermatological signs as possible early indicators of HCV infection and supports the effectiveness of direct-acting antivirals in resolving both hepatic and extrahepatic manifestations."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Hepatitis C • Immunology • Infectious Disease • Inflammation

Successful Use of Ultra-Short (7-Day) Hepatitis C Treatment Regimen in Adult Kidney Transplant Patients: A Single-Center Experience (WTC 2025) - "After clearing viremia with 12 weeks of sofosbuvir/velpatasvir - he recurred and was finally cured with 16 weeks of glecaprevir/pibrentasvir . Ultra-short 7-day therapy of Sofosbuvir/Velpatasvir in KT recipients from Hepatitis C (+) donors was tolerated well with 100% completion rate and prolonged viral suppression. A multi-disciplinary transplant team approach with adherence to treatment protocols and monitoring for drug-drug interaction can lead to successful viral suppression outcomes. Patients should be monitored closely for recurrence and can be successfully treated based on an individualized anti-viral therapeutic plan."

Clinical • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Transplantation

Successful Use of Belatacept in Patients Who Received HCV NAT(+) Kidneys and Receiving DAAs (WTC 2025) - "All but one patient received thymoglobulin for induction, the exception of one who received basiliximab. DAA therapy included glecaprevir/pibrentasvir (MAVYRET, 45.5%), sofosbuvir/velpatasvir (EPCLUSA, 40.9%) or sofosbuvir/ledipasvir (HARVONI, 13.6%)... Belatacept is not associated with HCV treatment failure or worsened graft outcome in the studied cohort. The rate of achieving SVR 12 was 97.7% within our cohort, which is comparable to prior studies."

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease

Glycemic Control in Thoracic Recipients of Hepatitis C Nucleic Acid Testing-Positive (HCV NAT+) Donor Organs (WTC 2025) - "The majority of NAT+ recipients were treated with glecaprevir/pibrentasvir (58.0%), with a mean time to treatment of 84.8 days.* No difference was found in glycemic control between thoracic transplant recipients of HCV NAT+ organs and HCV NAT- organs, suggesting potential evidence of the safe use of HCV NAT+ organs as a strategy to expand the donor pool.Table 1. No difference was found in glycemic control between thoracic transplant recipients of HCV NAT+ organs and HCV NAT- organs, suggesting potential evidence of the safe use of HCV NAT+ organs as a strategy to expand the donor pool.Table 1. Baseline CharacteristicsTable 2. Outcomes at 12 Months Post-Transplant"

Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Metabolic Disorders

Renal Transplant Outcomes with Dual-Infected HCV and HBV Viremic Donor Kidneys; the Hines VA Experience (WTC 2025) - "The patients received both Glecaprevir and pibrentasvir (Mavyret) and entecavir thirty minutes prior to surgery then post-operatively renally dose adjusted for one year (entecavir) and 60 days (Mavyret). This is the first series of the utilization of combined HCV NAT (+) and HBV NAT (+) donor kidneys. We show excellent graft function with no sequelae from either viral infection, The utilization of these "often-discarded" kidneys provide additional sources of grafts for elderly individuals with very little or no wait time and therefore may be an avenue to decreasing the number of discarded kidneys and reducing waitlist mortality."

Hepatitis B • Hepatitis C • Infectious Disease • Nephrology • Transplantation

Kidney Transplantation from Hepatitis C Viremic Donors and the Impact of Donor Liver Fibrosis - A Case Series (WTC 2025) - "After transplant, patients received sofosbuvir/velpatasvir or glecaprevir/pibrentasvir with sustained viral remission. Our data suggests that kidneys from HCV+ donors with significant liver fibrosis are more likely to exhibit baseline glomerular changes and poorer allograft outcomes, warranting caution in their use. Larger studies are needed to investigate this relationship and its implications for kidney transplant outcomes."

Clinical • Cardiovascular • CNS Disorders • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Transplantation

Efficacy and Safety of Glecaprevir/Pibrentasvir in Children Aged 3-11 Years With Chronic Hepatitis C: A Real-World, Prospective, Multicenter Study in Japan. (PubMed, Hepatol Res) - "In real-world clinical practice, G/P treatment demonstrated high efficacy and good tolerability in children aged 3-11 years with chronic HCV."

Clinical • Journal • Real-world evidence • Hepatitis C • Infectious Disease • Inflammation • Pediatrics • LGALS3BP

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

New P1/2 trial • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Prevalence, clinical correlations and outcomes of Cryoglobulinemic Vasculitis: a retrospective monocentric study (2013–2023) (EULAR 2025) - "Since the introduction of pan-genotypic regimens for the treatment of HCV in 2017 (e.g., Sofosbuvir/Velpatasvir and Glecaprevir/Pibrentasvir), the mean incidence of CV decreased from 8.4 cases (±1.7) during the period 2013–2017 to 3 cases (±1.6) during the period 2018–2023 ( p-value 0.001 )...Two-thirds of patients with CryoVas related to ADs received Rituximab (RTX), while Belimumab (BEL) was used exclusively in CryoVas related to ADs and essential CryoVas (10% and 8%, respectively)... CryoVas remains a significant clinical condition, with its etiology progressively evolving in recent years. Treatment approaches varied by etiology, with RTX serving as a cornerstone for CryoVas associated with ADs, while BEL demonstrated potential in select cases. Despite advancements in treatment and high rate of complete clinical response, relapse rates remain high, particularly in autoimmune-related CryoVas."

Retrospective data • Cardiovascular • Glomerulonephritis • Hematological Disorders • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Rheumatology • Sjogren's Syndrome • Vasculitis

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus (PRNewswire) - "AbbVie...announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. With this approval, MAVYRET is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate....The label expansion was supported by data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of MAVYRET eight-week treatment in adults with acute HCV infection."

FDA approval • Hepatitis C • Infectious Disease

The experience and outcomes of our centre’s first year accepting Hepatitis C positive deceased donor kidneys for transplantation (UKKW 2025) - "She then underwent a 16-week course of Epclusa to ensure a sustained virological response at 12 weeks following completion of treatment (SV12), and has successfully achieved SV12 clearance...She completed a 16-week course of Maviret with sustained virological response and no second course of treatment required...Of those that have gone ahead, 2 of 5 patients have developed active viraemia and both of these have been successfully treated. We are encouraged by this small number of results and will continue with this programme in the hopes that more of our patients will consent to HCV-positive donor kidneys in future, with ongoing good outcomes."

Hepatitis C • Hepatology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

Unexpected Findings of Liver Cirrhosis in Bariatric Surgery Patients: A Retrospective Analysis of Three Clinical Cases (ECO 2025) - "After antiviral therapy (Glecaprevir/Pibrentasvir 12 weeks in standard doses), no viral load was detected... Undiagnosed liver cirrhosis can present unexpected challenges in bariatric surgery. Preoperative assessment should incorporate advanced diagnostic modalities, such as liver fibrosis calculators and elastography/MRI, especially in high-risk patients. Despite intraoperative findings, LSG proved to be a safe and effective procedure for weight loss and metabolic improvement in patients with compensated cirrhosis."

Bariatric surgery • Retrospective data • Surgery • Cardiovascular • Diabetes • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Hepatitis B • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Obesity • Portal Hypertension • Thrombocytopenia • Type 2 Diabetes Mellitus

A global comparison of hepatitis B & C drug pricing. (PubMed, Ann Hepatol) - "HBV and HCV originator medications cost significantly more in the US compared to seven other major industrial countries. However, the introduction of HBV generic medications has lowered the cost of treatment for patients in the US. Future adoption of international reference pricing may help bridge remaining pricing disparities."

Journal • Pricing • Hepatitis B • Hepatitis C • Infectious Disease • Inflammation

TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION WITH GLECAPREVIR/PIBRENTASVIR IN PEDIATRIC AGE - THE REALITY OF A LEVEL III HOSPITAL (ESPGHAN 2025) - "At 12 weeks, SVR was confirmed in 8/8 patients. Conclusions Direct-acting antivirals provide an opportunity to treat HCV at earlier ages with shorter regimens, achieving high cure rates and no side effects."

Clinical • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Oncology • Pediatrics • Solid Tumor

GLECAPREVIR-PIBRENTASVIR IMPLEMENTATION FOR CHILDREN AGED 3-12 YEARS WITH CHRONIC HEPATITIS C: MULTICENTER REAL-WORLD DATA. (ESPGHAN 2025) - "Conclusions Our real-world data support clinical trials, showing GLE/PIB to be effective and well-tolerated for children aged 3-12 with chronic HCV. Early treatment may help prevent liver damage and lower transmission rates."

Clinical • Real-world • Real-world evidence • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pediatrics

COMPARATIVE STUDY DEMONSTRATING THE SUPERIORITY OF DIRECT-ACTING ANTIVIRALS OVER INTERFERON PLUS RIBAVIRIN IN ALBANIAN CHILDREN WITH CHRONIC HEPATITIS C (ESPGHAN 2025) - "The second group, comprising children aged 4 to 22*years (10 boys and 2 girls), [table 2] was treated with DAAs: half received HARVONI (Ledipasvir/Sofosbuvir) for 12 weeks, and the other half received MAVYRET (Glecaprevir/Pibrentasvir) for 8 weeks. They resulted in fewer side effects and shorter treatment duration. These findings highlight the superiority of DAAs and support the WHO recommendations for treating adults, adolescents, and children as young as 3 years old."

Clinical • Head-to-Head • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Pain • Pediatrics

TEMPORAL TRENDS IN HCV SCREENING, FOLLOW-UP TESTING, AND TREATMENT IN PREGNANT PEOPLE AND INFANTS IN AN ACADEMIC COUNTY HOSPITAL SETTING (DDW 2025) - "Of the 13 (25.5%) with HCV-related consults, none received antiviral therapy during pregnancy; 1 (7.7%) received postpartum antiviral therapy (with glecaprevir/pibrentasvir), and 12 (92.3%) were lost to follow-up... HCV screening in pregnancy has improved to 79.4% over the past 10 years, although remained lower than universal recommendations. While HCV viremia was < 1%, with no perinatal transmission, infant screening rates were low at 26%. This data supports the increased need for linkage of care for HCV infected birthing parents and infants, to enhance access to HCV screening and eradication."

Clinical • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Inflammation

RISK OF HEPATOCELLULAR CARCINOMA AFTER RECEIVING DIRECT ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITIS C VIRUS: MULTICENTRIC RETROSPECTIVE STUDY (DDW 2025) - "Subgroup analyses were performed for specific DAAAs combinations (Epclusa, Harvoni, Mavyret, Vosevi, and Zepatier). The findings highlight the importance of early DAAAs treatment in reducing the long-term complications of HCV. Further prospective studies with longer follow-up durations are warranted to confirm these associations."

Retrospective data • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Oncology • Solid Tumor

Real-world outcomes in patients with Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment failure: a follow-up study (EASL 2025) - "Most of the patients had been pre-treated with VEL/SOF (55%, 17/31), 13% (4/31) each had received G/P (glecaprevir/pibrentasvir) or GZR/EBR(grazoprevir/elbasvir)±SOF and 10% (3/31) each had been pretreated with LDV(ledipasvir)/SOF or DCV(daclatasvir)/SOF. The combination of G/P+SOF represents an effective third-line treatment option for difficult-to-treat patients, including those with cirrhosis, HCC, or HCV GT3 infection. These findings highlight the importance of tailored salvage therapy to achieve optimal outcomes in this challenging population."

Clinical • Real-world • Real-world evidence • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Oncology • Solid Tumor

Utilization of Organs from Hepatitis C-Antibody-Positive or RNA-Positive Donors in Kidney Transplantation: A Single-Center Retrospective Analysis of Outcomes and Safety. (PubMed, J Clin Med) - " This single-center study supports the safety of kidney transplantation from HCV-positive donors. Preemptive Glecaprevir/Pibrentasvir therapy effectively prevents HCV transmission, offering a viable option to expand the donor pool."

Journal • Retrospective data • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Transplantation